Orchid AMS
Your Partner in the Fight Against Antimicrobial Resistance
We provide hospitals with an ecosystem of advanced therapies, expert-led stewardship programs, and digital decision support.
Together, we implement evidence-based protocols that reduce Healthcare Associated Infections (HAIs), shorten Average Length of Stay (ALOS), and improve patient outcomes.
Partner With Us
Novel Medicine Portfolio
Breakthrough products addressing critical unmet needs in resistant infections.
Access to pathbreaking antimicrobials
Stewardship requires having the right tools for the right pathogen. Orchid AMS provides hospitals with access to an advanced portfolio designed to treat the most resistant pathogens while protecting legacy antibiotics.
ORBLICEF™ (Cefepime + Enmetazobactam)
A superior carbapenem-sparing option for ESBL infections. Enmetazobactam is the first indigenously invented NCE from India to receive US FDA approval, playing a vital role in protecting carbapenem utility.
ORTARO™ (Ceftaroline)
A 5th-generation cephalosporin with a unique affinity for PBP2a, making it the only beta-lactam active against MRSA.
Cefiderocol
Manufactured through our sub-license agreement with the Global Antibiotic Research and Development Partnership (GARDP). This "last-line" siderophore cephalosporin is highly active against NDM-1 and other metallo-beta-lactamases (MBLs) common in India
Formulations Portfolio
Our branded divisions combine manufacturing excellence with market-specific commercial strategies, ensuring high-quality medicine access across regulated and emerging markets.
Orchid AMS
OrchidAMS: Antimicrobial Stewardship & Critical Care
Positioned as our flagship hospital-focused division, OrchidAMS leads the charge in Antimicrobial Resistance (AMR) solutions.
Featured Portfolio
Antibacterial Agent
ORBLICEF
Cefepime-Enmetazobactam
Injectable
About
ORBLICEF
Therapeutic Category
Antibacterial Agent
Molecule
Cefepime-Enmetazobactam
Strengths
2.5g
Dose Form
Injectable
Thank you!
Your submission has been received successfully, our team will reach out to you soon!
Oops! Something went wrong while submitting the form.
Glycopeptide Antibiotic
ORPLANIN
Teicoplanin
Injectable
About
ORPLANIN
Therapeutic Category
Glycopeptide Antibiotic
Molecule
Teicoplanin
Strengths
400mg
Dose Form
Injectable
Thank you!
Your submission has been received successfully, our team will reach out to you soon!
Oops! Something went wrong while submitting the form.
Antibiotic Agent
ORCOSTIN
Colistimethate Sodium
Injectable
About
ORCOSTIN
Therapeutic Category
Antibiotic Agent
Molecule
Colistimethate Sodium
Strengths
1 MIU, 2 MIU, 3 MIU, 4.5 MIU
Dose Form
Injectable
Thank you!
Your submission has been received successfully, our team will reach out to you soon!
Oops! Something went wrong while submitting the form.
Antibiotic
ORZID-AV
Ceftazidime + Avibactam
Injectable
About
ORZID-AV
Therapeutic Category
Antibiotic
Molecule
Ceftazidime + Avibactam
Strengths
2.5g
Dose Form
Injectable
Thank you!
Your submission has been received successfully, our team will reach out to you soon!
Oops! Something went wrong while submitting the form.
Monobactam Antibiotic
ORAZONAM
Aztreonam
Injectable
About
ORAZONAM
Therapeutic Category
Monobactam Antibiotic
Molecule
Aztreonam
Strengths
1g
Dose Form
Injectable
Thank you!
Your submission has been received successfully, our team will reach out to you soon!
Oops! Something went wrong while submitting the form.
Antibacterial Agent
ORCEFO-SB
Cefoperazone + Sulbactam
Injectable
About
ORCEFO-SB
Therapeutic Category
Antibacterial Agent
Molecule
Cefoperazone + Sulbactam
Strengths
1.5g
Dose Form
Injectable
Thank you!
Your submission has been received successfully, our team will reach out to you soon!
Oops! Something went wrong while submitting the form.
Antibiotic Agent
ORFUCEF
Cefuroxime-Axetil
Oral Tablet
About
ORFUCEF
Therapeutic Category
Antibiotic Agent
Molecule
Cefuroxime-Axetil
Strengths
500mg
Dose Form
Oral Tablet
Thank you!
Your submission has been received successfully, our team will reach out to you soon!
Oops! Something went wrong while submitting the form.
Antibiotic agent
ORTARO
Ceftaroline
Injectable
About
ORTARO
Therapeutic Category
Antibiotic agent
Molecule
Ceftaroline
Strengths
600mg
Dose Form
Injectable
Thank you!
Your submission has been received successfully, our team will reach out to you soon!
Oops! Something went wrong while submitting the form.
Antibiotic Agent
ORCIX
Cefixime
Oral Tablet
About
ORCIX
Therapeutic Category
Antibiotic Agent
Molecule
Cefixime
Strengths
200mg
Dose Form
Oral Tablet
Thank you!
Your submission has been received successfully, our team will reach out to you soon!
Oops! Something went wrong while submitting the form.
Antibiotic agent
ORIAXON
Ceftriaxone
Injectable
About
ORIAXON
Therapeutic Category
Antibiotic agent
Molecule
Ceftriaxone
Strengths
1g
Dose Form
Injectable
Thank you!
Your submission has been received successfully, our team will reach out to you soon!
Oops! Something went wrong while submitting the form.
Antifungal Agent
ORAMPHO
Liposomal Amphotericin B
Injectable
About
ORAMPHO
Therapeutic Category
Antifungal Agent
Molecule
Liposomal Amphotericin B
Strengths
50mg
Dose Form
Injectable
Thank you!
Your submission has been received successfully, our team will reach out to you soon!
Oops! Something went wrong while submitting the form.
Antibiotic Agent
MEROMER
Meropenem
Injectable
About
MEROMER
Therapeutic Category
Antibiotic Agent
Molecule
Meropenem
Strengths
500mg, 1g
Dose Form
Injectable
Thank you!
Your submission has been received successfully, our team will reach out to you soon!
Oops! Something went wrong while submitting the form.
Antibiotic Agent
ORVANCIN
Vancomycin
Injectable
About
ORVANCIN
Therapeutic Category
Antibiotic Agent
Molecule
Vancomycin
Strengths
500mg, 1g
Dose Form
Injectable
Thank you!
Your submission has been received successfully, our team will reach out to you soon!
Oops! Something went wrong while submitting the form.
Antibacterial Agent
ORTAZILIN
Piperacillin + Tazobactam
Injectable
About
ORTAZILIN
Therapeutic Category
Antibacterial Agent
Molecule
Piperacillin + Tazobactam
Strengths
4.5g
Dose Form
Injectable
Thank you!
Your submission has been received successfully, our team will reach out to you soon!
Oops! Something went wrong while submitting the form.
Anti-Microbial Stewardship Program
Breakthrough products addressing critical unmet needs in resistant infections.
Trusted by India’s Leading Healthcare Institutions
"Wonderful initiative by Orchid Pharma. We now have a very strong clinician engagement."
.webp)
"Our Pharmacists are now able to have better audit compliance."
.webp)
"Thanks to Orchid Pharma, we now have improved interdisciplinary collaboration."
"Reduced empirical escalation and surgical prophylaxis improvement is visible."
.webp)
"Wonderful initiative by Orchid Pharma. We now have a very strong clinician engagement."
"Our Pharmacists are now able to have better audit compliance."
"Thanks to Orchid Pharma, we now have improved interdisciplinary collaboration."
"Reduced empirical escalation and surgical prophylaxis improvement is visible."
Our methodology
The triple shield approach
Effective containment of Antimicrobial Resistance requires more than just restricting prescriptions. Orchid AMS operationalizes the comprehensive triple shield approach to combat AMR effectively at all levels.
Pillar 1
Infection Prevention and Control (IPC)
Actively reduce the overall need for antimicrobial use. Partner hospitals have seen a 10 to 20% reduction in Healthcare Associated Infections through structured IPC protocols.
Pillar 2
Diagnostic Stewardship
Ensure accurate, evidence-based treatment and prophylaxis rather than prolonged empirical therapy. Move from guesswork to culture-driven prescribing with unit-specific antibiograms for OPD, ward, and ICU.
Pillar 3
Antimicrobial Stewardship (AMS)
Optimize selection, dosing, and duration of antimicrobial therapies. Real-time audit and feedback loops sustain prescribing discipline and drive a 20 to 35% reduction in broad-spectrum antibiotic use.
Partnership model
A multi-dimensional approach to strengthen your hospital's AMR defense.
We partner with hospitals to deliver transformative excellence. Our Antimicrobial Stewardship Program (AMSP) embeds seamlessly into your existing workflows.
Our 5-step engagement process
We follow a structured, collaborative methodology to assess, design, and implement your customized stewardship program:
01
Confidentiality Agreement (CDA)
We establish trust and secure information handling from day one.
02
Two-Day On-Site Audit
A comprehensive policy review, prescription audit, and an in-depth microbiology and pharmacy assessment.
03
Stakeholder Engagement
Direct interactions with your clinicians to understand daily workflows, identify pain points, and uncover clinical opportunities.
04
Leadership Presentation
We deliver our final findings and strategic recommendations directly to your hospital leadership team.
05
Detailed Roadmap
We provide a comprehensive implementation plan complete with timelines, Key Performance Indicators (KPIs), and a sustainable governance model.
Our stewardship partners
Transformation track record includes
Real-time intelligence at the point of care
Our digital tools do not replace clinical judgment. They sharpen it. Orchid AMS integrates data-driven decision support directly into your hospital's existing workflow.
.webp)
The strategic & financial impact of AMSP
Implementing our data-driven stewardship program eliminates hidden inefficiencies, unlocking significant clinical and financial value for your institution.
30%
Reduced Drug Costs
A 15% to 30% reduction in antibiotic spending, saving approximately ₹1.5 to ₹3.5 Crores annually
₹6 Cr
Capacity value
Decreased Length of Stay (ALOS)
Shortening overall ALOS by 0.5 to 1.2 days per infection episode, and ICU ALOS by 0.3 to 0.8 days, which unlocks ₹3 to ₹6 Crores in capacity value.
₹2 Cr
In savings
Fewer Complications
Avoiding empirical escalations, repeat cultures, and prolonged ICU care yields an estimated ₹1 to ₹2 Crores in savings.
~35%
Reduction in broad-spectrum
Measurable Clinical Improvements
Hospitals typically see a ~35% reduction in broad-spectrum antibiotic use, a ~20% decrease in HAIs and multidrug-resistant (MDR) infections, and an 8% to 15% drop in patient readmissions.
